In the two years since the Tear Film & Ocular Surface Society second Dry Eye Workshop (TFOS DEWS II) reports were published, most would agree that dry eye disease (DED) is closer to reaching household
Inflammation has been implicated in the pathogenesis of dry eye disease (DED)1,2, most notably in conditions such as Sjögren’s syndrome. However, in meibomian gland disease, considered the most
It’s been full steam ahead for the Ocular Surface Laboratory (OSL) this year in the wake of TFOS DEWS II, ably assisted by Dr Alex Muntz, who joined the team in 2018. Research in the lab has continued
Virtually all patients encounter streams of salty water coursing down their cheeks early in life and don’t realise they have more than one type of tears. More widely recognised, reflex tears serve as
After many years of preparation, a dedicated dry eye clinic at the Montreal School of Optometry was inaugurated in 2012, a first within a North American Optometry school. Beginning with only half a
Eye care practitioners are well aware that medications for patients with ocular surface disease need to be proven safe through clinical trials. They probably also assume, like their patients, that
July 2019 marked the evolution and merger of ODMA and the SRC conference into O=Mega, complete with trade fair, clinical lectures, dispensing master classes and all the social stuff. The conference
On Saturday morning, the much anticipated and very well attended Optical Dispenser Forum took place in a conference room at O=Mega19 at the Melbourne Convention Centre.The forum was moderated by
The much-anticipated, inaugural O=Mega19 optical fair and conference opened to a queue of attendees on a bright but cold, winter’s day in Melbourne on 19 July.Tucked as far away as humanly possible
IMAGE CAPTION|Attending the AUSCRS Lord of the Rings gala dinner. Credit: Sam Boden Photography
If you had asked me on my BOptom graduation day what I thought I’d be working on in five years’ time, I would not have imagined it would be a clinical trial with a team of neurologists and
Patients suffering from age-related macular degeneration (AMD) can feel encouraged by the latest therapeutic discoveries.
